sodium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4487	25704-18-1

Description:

Molecule	Description
Synonyms: kayexalate sodium polystyrene sulfonate sodium p-styrenesulfonate homopolymer	A potassium ion exchange resin composed of benzene-diethyl polymer with ethenyl-benzene, sulfonated, sodium salt. Administered as an oral suspension, sodium polystyrene sulfonate lowers serum potassium levels by exchanging its sodium ions for potassium ions. Acting primarily in the large intestine, this agent also exchanges its sodium ions for calcium and magnesium ions, resulting in a decrease in serum calcium and magnesium levels. Molecular weight: Formula: (C8H7NaO3S)n CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

kayexalate
sodium polystyrene sulfonate
sodium p-styrenesulfonate homopolymer

A potassium ion exchange resin composed of benzene-diethyl polymer with ethenyl-benzene, sulfonated, sodium salt. Administered as an oral suspension, sodium polystyrene sulfonate lowers serum potassium levels by exchanging its sodium ions for potassium ions. Acting primarily in the large intestine, this agent also exchanges its sodium ions for calcium and magnesium ions, resulting in a decrease in serum calcium and magnesium levels.

Molecular weight:
Formula: (C8H7NaO3S)n
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
45	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 5, 1958	FDA	CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypokalaemia	112.46	26.30	69	3252	103735	63381966
Hyperkalaemia	105.41	26.30	53	3268	54150	63431551
Acute kidney injury	82.38	26.30	84	3237	263331	63222370
Arteriovenous fistula occlusion	77.89	26.30	14	3307	365	63485336
Blue toe syndrome	76.89	26.30	14	3307	393	63485308
Urinary retention	62.89	26.30	31	3290	30270	63455431
Facial nerve disorder	60.04	26.30	12	3309	557	63485144
Metabolic alkalosis	57.87	26.30	16	3305	3045	63482656
Crystal deposit intestine	51.34	26.30	8	3313	84	63485617
Head injury	45.15	26.30	24	3297	27372	63458329
Pneumonia aspiration	42.57	26.30	25	3296	34515	63451186
Granulomatous liver disease	39.64	26.30	9	3312	769	63484932
Renal impairment	38.60	26.30	34	3287	88321	63397380
Renal pain	38.21	26.30	14	3307	6585	63479116
Lactic acidosis	37.68	26.30	24	3297	38263	63447438
Left ventricular hypertrophy	37.29	26.30	13	3308	5302	63480399
Muscle strain	35.13	26.30	14	3307	8260	63477441
Blood potassium increased	32.90	26.30	17	3304	18292	63467409
Drug reaction with eosinophilia and systemic symptoms	30.32	26.30	20	3301	33816	63451885
Gastrointestinal necrosis	28.23	26.30	9	3312	2789	63482912
Drug interaction	28.03	26.30	46	3275	229085	63256616
Fall	27.33	26.30	62	3259	392272	63093429

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Crystal deposit intestine	152.25	19.42	24	4879	87	34951941
Hyperkalaemia	148.26	19.42	102	4801	69287	34882741
Acute kidney injury	82.16	19.42	150	4753	304838	34647190
Hypocalcaemia	32.36	19.42	27	4876	24262	34927766
Large intestinal ulcer	29.82	19.42	11	4892	1958	34950070
Renal failure	29.70	19.42	60	4843	130497	34821531
Toxic skin eruption	29.68	19.42	19	4884	11366	34940662
Hypoprothrombinaemia	27.17	19.42	7	4896	375	34951653
Gastrointestinal necrosis	27.10	19.42	12	4891	3417	34948611
Chronic kidney disease	26.91	19.42	31	4872	41179	34910849
Lip ulceration	26.57	19.42	8	4895	761	34951267
Nephroangiosclerosis	26.35	19.42	6	4897	190	34951838
Large intestine perforation	24.19	19.42	15	4888	8488	34943540
Biopsy liver	24.15	19.42	6	4897	277	34951751
Burns second degree	23.54	19.42	8	4895	1121	34950907
Eosinophilia	22.88	19.42	23	4880	26199	34925829
Ileal perforation	22.35	19.42	7	4896	759	34951269
Metabolic acidosis	22.27	19.42	29	4874	43651	34908377
Biopsy rectum abnormal	21.54	19.42	3	4900	3	34952025
Anaemia	20.95	19.42	76	4827	233259	34718769
Tumour lysis syndrome	20.74	19.42	18	4885	17041	34934987
Aplasia pure red cell	20.50	19.42	12	4891	6120	34945908

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	229.25	18.55	143	7920	114255	79622070
Crystal deposit intestine	192.41	18.55	31	8032	197	79736128
Acute kidney injury	145.09	18.55	217	7846	519187	79217138
Hypokalaemia	78.06	18.55	84	7979	143956	79592369
Arteriovenous fistula occlusion	68.98	18.55	15	8048	537	79735788
Blue toe syndrome	62.46	18.55	14	8049	577	79735748
Gastrointestinal necrosis	55.60	18.55	21	8042	5544	79730781
Renal failure	54.37	18.55	83	7980	200885	79535440
Hypocalcaemia	54.25	18.55	43	8020	49881	79686444
Metabolic alkalosis	52.43	18.55	19	8044	4470	79731855
Facial nerve disorder	49.31	18.55	12	8051	710	79735615
Anaemia	46.07	18.55	123	7940	444892	79291433
Eosinophilia	44.91	18.55	37	8026	45308	79691017
Large intestinal ulcer	43.97	18.55	17	8046	4780	79731545
Metabolic acidosis	34.29	18.55	42	8021	82487	79653838
Large intestine perforation	33.66	18.55	20	8043	14547	79721778
Tumour lysis syndrome	33.51	18.55	24	8039	23915	79712410
Renal impairment	32.93	18.55	58	8005	157725	79578600
Blood potassium increased	31.33	18.55	25	8038	29250	79707075
Urinary retention	30.57	18.55	33	8030	56597	79679728
Biopsy rectum abnormal	30.03	18.55	4	8059	4	79736321
Hepatitis cholestatic	29.38	18.55	18	8045	13834	79722491
Renal pain	29.11	18.55	15	8048	8281	79728044
Head injury	27.96	18.55	26	8037	37343	79698982
Excessive granulation tissue	27.46	18.55	8	8055	944	79735381
Drug interaction	27.26	18.55	98	7965	415085	79321240
Aplasia pure red cell	27.05	18.55	14	8049	7796	79728529
Cardiac failure	26.16	18.55	52	8011	154790	79581535
Intestinal ischaemia	25.01	18.55	16	8047	13254	79723071
Nephroangiosclerosis	24.85	18.55	6	8057	343	79735982
Hypoprothrombinaemia	24.83	18.55	7	8056	735	79735590
Granulomatous liver disease	24.81	18.55	8	8055	1325	79735000
Lactic acidosis	24.79	18.55	33	8030	70326	79665999
Pneumonia aspiration	24.51	18.55	32	8031	66935	79669390
Muscle strain	24.41	18.55	14	8049	9541	79726784
Hyperphosphataemia	23.74	18.55	12	8051	6364	79729961
Pain	23.49	18.55	22	8041	703780	79032545
Chronic kidney disease	23.27	18.55	31	8032	66123	79670202
Lymphocele	22.99	18.55	8	8055	1673	79734652
Gastrointestinal injury	22.89	18.55	7	8056	976	79735349
Ileal perforation	22.60	18.55	7	8056	1018	79735307
Left ventricular hypertrophy	22.36	18.55	14	8049	11177	79725148
Toxic skin eruption	21.67	18.55	18	8045	22275	79714050
Biopsy liver	21.36	18.55	6	8057	622	79735703
Hypothermia	21.35	18.55	18	8045	22728	79713597
Thrombocytopenia	21.26	18.55	67	7996	265192	79471133
Rectal ulcer	21.23	18.55	8	8055	2096	79734229
Sickle cell anaemia	21.03	18.55	6	8057	658	79735667
Lip ulceration	20.46	18.55	8	8055	2317	79734008
Peritonitis	20.00	18.55	19	8044	28017	79708308
Burns second degree	19.51	18.55	8	8055	2620	79733705
Hypoaldosteronism	19.31	18.55	5	8058	381	79735944
Cholestasis	19.22	18.55	25	8038	52084	79684241
Diffuse alopecia	18.77	18.55	6	8057	967	79735358

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA	N0000175357	Potassium Ion Exchange Activity
MeSH PA	D002411	Cation Exchange Resins
MeSH PA	D002614	Chelating Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D064449	Sequestering Agents
FDA EPC	N0000178378	Potassium Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009
Hypocalcemia	contraindication	5291005
Bowel sounds absent	contraindication	16268000
Alkalosis	contraindication	21420006
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Hypovolemia	contraindication	28560003
Ischemic colitis	contraindication	30588004	DOID:0060181
Hypokalemia	contraindication	43339004
Fecal impaction	contraindication	44635007
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Gastrointestinal hemorrhage	contraindication	74474003
Intestinal obstruction	contraindication	81060008	DOID:8437
Chronic idiopathic constipation	contraindication	82934008
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Hypomagnesemia	contraindication	190855004
Edema	contraindication	267038008
Operation on gastrointestinal tract	contraindication	386621005
Gastrointestinal hypomotility	contraindication	421807004
Hypertensive urgency	contraindication	443482000
Colonic Necrosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D03263	KEGG_DRUG
4018241	VANDF
CHEBI:53279	CHEBI
CHEBI:53277	CHEBI
CHEMBL1201484	ChEMBL_ID
C003321	MESH_SUPPLEMENTAL_RECORD_UI
1699G8679Z	UNII
DB01344	DRUGBANK_ID
1546437	RXNORM
1125	MMSL
1264	MMSL
5492	MMSL
d00743	MMSL
000753	NDDF
006664	NDDF
1002242008	SNOMEDCT_US
387149008	SNOMEDCT_US
710808009	SNOMEDCT_US
C0142915	UMLSCUI
C0137904	UMLSCUI
8324	INN_ID
28210-41-5	SECONDARY_CAS_RN
58817179	PUBCHEM_CID
ZSL2FB6GXN	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-146	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-146	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-036	POWDER	1 g	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	11534-166	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	11534-166	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0024	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0036	POWDER	1 g	ORAL	ANDA	14 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0831	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	18 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1136	POWDER	1 g	ORAL	ANDA	14 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	24658-760	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	24658-760	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	42806-013	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	42806-013	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	46287-006	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	46287-012	POWDER, FOR SUSPENSION	1 g	ORAL	ANDA	24 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	50488-5001	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	51293-831	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	24 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	51293-831	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	24 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	55154-7353	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	55154-7353	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	62135-340	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	62135-340	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	62250-660	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	12 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	62250-660	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	12 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2031	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2031	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2031	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2390	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2390	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2390	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections